Huan He

US Patent:

6900210, May 31, 2005

Filed:

Nov 21, 2003

Appl. No.:

10/719538

Inventors:

Yong-Jin Wu - Madison CT, US
Li-Qiang Sun - Glastonbury CT, US
Jie Chen - Madison CT, US
Huan He - Wallingford CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D213/643
C07D239/34
C07D241/18
A61K031/4412
A61K031/513

US Classification:

5142521, 514274, 514314, 514336, 514351, 544316, 544408, 546175, 5462804, 5462814, 5462834, 5462847, 546300

Abstract:

The present invention provides novel heterocyclic amides and related derivatives having the general Formula I wherein R, R, R, R, R, R, A, B and Z are as defined in the specification, or a nontoxic pharmaceutically acceptable salt, solvate or hydrate thereof which are openers or activators of KCNQ potassium channels. The present invention also provides pharmaceutical compositions comprising said heterocyclic amides and to the method of treatment of disorders sensitive to KCNQ potassium channel opening activity such as migraine or a migraine attack, bipolar disorders, epilepsy, acute and chronic pain and anxiety.

US Patent:

7045551, May 16, 2006

Filed:

Nov 21, 2003

Appl. No.:

10/719465

Inventors:

Yong-Jin Wu - Madison CT, US
Li-Qiang Sun - Glastonbury CT, US
Huan He - Wallingford CT, US
Alexandre L'Heureux - Longueuil, CA

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31/165
A61K 31/34
A61K 31/535
C07D 265/30
C07D 307/78

US Classification:

514617, 514471, 5142382, 564182, 549468, 544169

Abstract:

The present invention provides novel aryl hydroxyethyl amides and related derivatives having the general Formula I.

US Patent:

7098203, Aug 29, 2006

Filed:

Jul 18, 2005

Appl. No.:

11/183691

Inventors:

Yong-Jin Wu - Madison CT, US
Huan He - Wallingford CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61P 25/00
A61K 31/55
C07D 223/04

US Classification:

51421201, 540609, 540610

Abstract:

The present disclosure relates to chemical compounds and their use in human therapy. In a specific embodiment, compounds of Formula (I) or an isomer, a pharmaceutically acceptable salt or solvate thereof or a pharmaceutically acceptable formulation comprising said compounds.

US Patent:

7135472, Nov 14, 2006

Filed:

Nov 21, 2003

Appl. No.:

10/719187

Inventors:

Yong-Jin Wu - Madison CT, US
Alexandre L'Heureux - Longueuil, CA
Huan He - Wallingford CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31/50
A61K 31/496
C07D 213/44
C07D 413/00
C07D 233/54

US Classification:

514252, 51425503, 514256, 514318, 544335, 544358, 546234, 546262, 5462681, 5462687, 5462691, 5462695, 5462747, 5462764, 5462781, 5462791, 546336, 548146, 548235, 548247, 5483381, 5483741, 548537

Abstract:

The present invention provides novel 3-heterocyclic benzylamides and related derivatives having the general Formula I.

US Patent:

7138423, Nov 21, 2006

Filed:

Jul 18, 2005

Appl. No.:

11/183702

Inventors:

Yong-Jin Wu - Madison CT, US
Huan He - Tallahassee FL, US
Joanne J. Bronson - Durham CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A01N 43/36
A01N 43/38
C07D 207/08
C07D 209/14

US Classification:

514408, 514413, 514422, 548518, 548469, 548560, 548577

Abstract:

The present disclosure relates to chemical compounds and their use in treatment of human diseases. A particular embodiment relates to compounds of Formula (I) or an isomer, a pharmaceutically acceptable salts or solvates thereof or a pharmaceutically acceptable formulation comprising said compounds.

US Patent:

7276631, Oct 2, 2007

Filed:

Jul 18, 2005

Appl. No.:

11/183700

Inventors:

Yong-Jin Wu - Madison CT, US
Huan He - Wallingford CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07C 243/00
A01N 31/00

US Classification:

564462, 514508, 514712, 514716, 514719, 514724, 564453, 564501, 548400, 546184

Abstract:

The present disclosure relates to chemical compounds and their use in human therapy. A specific embodiment of the disclosure relates to compounds of Formula (I); or an isomer, a pharmaceutically acceptable salt or solvate thereof or a pharmaceutically acceptable formulation comprising said compounds.

US Patent:

7494986, Feb 24, 2009

Filed:

Jul 18, 2005

Appl. No.:

11/183699

Inventors:

Yong-Jin Wu - Madison CT, US
Huan He - Wallingford CT, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A01N 43/00
A61K 31/33
C07D 225/00
C07D 295/00

US Classification:

514183, 540450

Abstract:

The present disclosure relates to chemical compounds and their use in human therapy. A specific embodiment relates to compounds of Formula (I) or an isomer, a pharmaceutically acceptable salt or solvate thereof and pharmaceutically acceptable formulations comprising said compounds.

US Patent:

20030166650, Sep 4, 2003

Filed:

May 31, 2002

Appl. No.:

10/160582

Inventors:

Yong-Jin Wu - Madison CT, US
Jie Chen - Madison CT, US
Huan He - Wallingford CT, US
Alexandre L'Heureux - Longueuil, CA
Pierre Dextraze - Laprairie, CA
Jean-Paul Daris - St. Hubert, CA
Gene Kinney - Collegeville PA, US
Steven Dworetzky - Middlefield CT, US
Piyasena Hewawasam - Middletown CT, US

International Classification:

A61K031/5377
A61K031/47
A61K031/501
A61K031/506
A61K031/497
A61K031/44
A61K031/353
A61K031/165

US Classification:

514/231500, 514/311000, 514/357000, 514/438000, 514/456000, 514/467000, 514/252010, 514/256000, 514/255050, 514/252030, 514/252040, 514/617000, 544/128000, 544/131000, 544/145000, 514/149000, 544/238000, 544/333000, 544/405000, 546/176000, 546/336000, 549/401000, 549/438000, 564/161000

Abstract:

There is provided novel cinnamide derivatives of Formula I wherein R is Calkyl or trifluoromethyl; Ris selected from the group consisting of pyridinyl, quinolinyl, thienyl, furanyl, 1,4-benzodioxanyl, 1,3-benzodioxolyl, chromanyl, indanyl, biphenylyl, phenyl and substituted phenyl in which said substituted phenyl is substituted with one or two substituents each independently selected-from the group consisting of halogen, Calkyl, Calkoxy, trifluoromethyl, trifluoromethoxy and nitro; Rand Rare each independently selected from the group consisting of hydrogen, Calkyl, and halogen; Ris selected from the group consisting of di(Calkyl)amino, trifluoromethoxy and optionally substituted morpholin-4-yl, pyridinyl, pyrimidinyl, piperazinyl, and pyrazinyl with one or two substituents in which said substituent is independently selected from the group consisting of Calkyl, aminomethyl, hydroxymethyl, chloro or fluoro; Ris hydrogen, chloro or fluoro; or Rand Rtaken together are —CH CH—CH CH— or —X(CH)Y— in which X and Y are each independently selected from the group consisting of CH, (CH)N(R)— and O, wherein m is 1 or 2; n is 0 or 1; and R, R, and Rare each independently selected from hydrogen, chloro and fluoro; and Ris selected from the group consisting of hydrogen, Calkyl, hydroxyethyl, Calkoxyethyl, cyclopropylmethyl, —CO(Calkyl), and —CHCHNRRin which Rand Rare each independently hydrogen or Calkyl, which are openers of the KCNQ potassium channels and are useful in the treatment of disorders which are responsive to the opening of the KCNQ potassium channels.